Medicines advice

Search Filters

Know what you're looking for?

Submission type

British National Formulary - Chapter

Pharmaceutical company

From

To

Advice

Accepted Not recommended Restricted Superseded Withdrawn Interim acceptance

Process

End of life/orphan Ultra orphan

Additional Details

Patient Access Scheme

Advanced Search

SMC ID	Date	Medicine	Submission Type	Indication
SMC2100	09/07/2018	midostaurin (Rydapt)	Non submission	as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.
1330/18	11/06/2018	midostaurin (Rydapt) for AML	Full	Treatment of adult patients with newly diagnosed acute myeloid leukaemia who are FLT3 mutation positive in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy.

No medicines have been found.